Cancer-Stricken Girl in Remission After Family Raises $180K for Experimental Treatment
Erin Cross, 6, was released from Seattle Children's Hospital after undergoing an experimental treatment designed to utilize her immune system to fight cancer. The girl was diagnosed with acute lymphoblastic leukemia at age 2, and while initial treatment put Erin in remission, she eventually relapsed. That’s when Erin's mother, Sarah Cross, said the family started to look at other options and became more interested in the technology where doctors re-engineer a patient's own t-cells to fight cancer, part of a growing treatment field called immunotherapy. After undergoing the treatment, Erin has had no signs of leukemia in her cells. Dr. Rebecca Gardner from Seattle Children’s is quoted in the article.
About Seattle Children’s
Seattle Children’s mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children’s Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.
Ranked as one of the top children’s hospitals in the country by U.S. News & World Report, Seattle Children’s serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest region of any children’s hospital in the country. As one of the nation's top five pediatric research centers, Seattle Children’s Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children’s Hospital and Research Foundation works with the Seattle Children’s Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research.
For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.